Publicaciones en las que colabora con JOSÉ LUIS CABRIADA NUÑO (129)

2024

  1. An in vitro analysis of the interaction between infliximab and granulocyte–monocyte apheresis

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 347-351

  2. Combination of granulocyte–monocyte apheresis and tofacitinib: Multicentre and retrospective study

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 7, pp. 727-733

  3. Combination of granulocyte–monocyte apheresis and ustekinumab: Multicentre and retrospective study

    Gastroenterologia y Hepatologia

  4. Environmental Exposure to Trace Elements and Heavy Metals Preceding the Clinical Onset of Inflammatory Bowel Disease

    Crohn's and Colitis 360, Vol. 6, Núm. 1

  5. Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 5, pp. 604-612

  6. Transmural cross-sectional findings and bowel damage assessment in preclinical Crohn’s disease: a case-control study

    International Journal of Colorectal Disease, Vol. 39, Núm. 1

  7. Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA

    Pharmaceutics, Vol. 16, Núm. 5

2023

  1. Development of a Prediction Model for Short-Term Remission of Patients with Crohn’s Disease Treated with Anti-TNF Drugs

    International Journal of Molecular Sciences, Vol. 24, Núm. 10

  2. Hemoperitoneum due to rupture of intra-abdominal varices

    Revista espanola de enfermedades digestivas, Vol. 115, Núm. 2, pp. 97

  3. Liver abscess due to parvimonas micra

    Revista espanola de enfermedades digestivas, Vol. 115, Núm. 2, pp. 89-90

  4. Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU

    American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046

  5. Subclinical bowel inflammation increases healthcare resources utilization and steroid use before diagnosis of inflammatory bowel disease

    United European Gastroenterology Journal, Vol. 11, Núm. 1, pp. 9-18

2022

  1. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  2. Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity

    Biomedicines, Vol. 10, Núm. 3

  3. Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU

    Journal of Crohn's & colitis, Vol. 16, Núm. 7, pp. 1049-1058

  4. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

  5. Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU

    Journal of Clinical Medicine, Vol. 11, Núm. 13

  6. Polycystic pancreas, gastrointestinal manifestation of von Hippel-Lindau disease

    Gastroenterologia y Hepatologia, Vol. 45, pp. 73-74

  7. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

2021

  1. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry

    Journal of Hepatology, Vol. 75, Núm. 1, pp. 86-97